ENTITY
BeiGene

BeiGene (6160 HK)

341
Analysis
Health CareChina
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
Exchange Announcement08 Jan 2025 20:43
Exchange Announcement08 Jan 2025 12:00
Exchange Announcement06 Jan 2025 21:08
Exchange Announcement02 Jan 2025 08:03
Exchange Announcement30 Dec 2024 08:00
x